XTL Biopharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2015
Net Income	-1.03	-1.78	-1.35	0.44	-2.95	Upgrade
Depreciation & Amortization	0.2	-	0	0	0	Upgrade
Loss (Gain) From Sale of Investments	-0.17	1.02	1.53	-0.75	-0.14	Upgrade
Stock-Based Compensation	0.26	0	0.01	0.04	0.05	Upgrade
Other Operating Activities	-1.08	-0.01	-1.08	-0.72	2.15	Upgrade
Change in Accounts Receivable	0.04	-	-	-	-	Upgrade
Change in Accounts Payable	0.21	0.02	-0.04	-0.02	0.02	Upgrade
Change in Other Net Operating Assets	-0.06	0.05	0.03	-0.03	0.02	Upgrade
Operating Cash Flow	-1.62	-0.71	-0.9	-1.05	-0.85	Upgrade
Capital Expenditures	-0.05	-	-	-	-0	Upgrade
Cash Acquisitions	-0.41	-	-	-	-	Upgrade
Investment in Securities	-0.01	-	-	-	-	Upgrade
Other Investing Activities	0.03	0.04	0.04	0.01	0.03	Upgrade
Investing Cash Flow	-0.84	0.04	0.04	0.01	0.03	Upgrade
Long-Term Debt Repaid	-0.01	-	-	-	-	Upgrade
Net Debt Issued (Repaid)	-0.01	-	-	-	-	Upgrade
Issuance of Common Stock	1.46	-	-	0.39	-	Upgrade
Financing Cash Flow	1.45	-	-	0.39	-	Upgrade
Foreign Exchange Rate Adjustments	-0.02	-0.03	-0.01	-0.01	-0.01	Upgrade
Net Cash Flow	-1.03	-0.69	-0.88	-0.66	-0.82	Upgrade
Free Cash Flow	-1.67	-0.71	-0.9	-1.05	-0.85	Upgrade
Free Cash Flow Margin	-370.73%	-	-	-	-	Upgrade
Free Cash Flow Per Share	-0.00	-0.00	-0.00	-0.00	-0.00	Upgrade
Levered Free Cash Flow	0.74	-0.41	-0.55	-0.66	-0.5	Upgrade
Unlevered Free Cash Flow	0.76	-0.41	-0.55	-0.66	-0.5	Upgrade
Change in Working Capital	0.19	0.06	-0.02	-0.05	0.05	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.